Affiliation:
1. The Foundation for Orthopaedics and Regenerative Medicine, Glenview, IL, USA
Abstract
Background:
Mesenchymal stem cells (MSCs) have been shown to decrease inflammation and
enhance healing due to their immunomodulatory properties and secretion of growth factors. Intravenous
infusion is the most common delivery route of MSCs, and it is used for the treatment of a wide variety of
conditions, with established efficacy.
Objective:
This review will analyze the safety of intravenous infusion of MSCs and determine the incidence
of any possible resultant Serious Adverse Events (SAEs).
Methods:
Using PubMed, we searched the scientific literature to identify SAEs related to intravenous
infusion of MSCs. We performed disease-specific searches and a general adverse event search.
Results:
A total of 70 studies were included in this review. Thousands of infusions were administered and
only two SAEs were identified from the same study. The SAEs were two upper extremity thromboembolisms
in patients with preexisting renal disease.
Conclusion:
Properly performed intravenous infusion of MSCs is very safe, with a near absence of reported
serious adverse events associated with its use.
Publisher
Bentham Science Publishers Ltd.
Subject
General Medicine,Medicine (miscellaneous)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献